<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5637">
  <stage>Registered</stage>
  <submitdate>26/09/2012</submitdate>
  <approvaldate>26/09/2012</approvaldate>
  <nctid>NCT01695876</nctid>
  <trial_identification>
    <studytitle>A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects</studytitle>
    <scientifictitle />
    <utrn />
    <trialacronym />
    <secondaryid>Inflammation</secondaryid>
    <secondaryid>20110246</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Inflammatory Disease</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 357
Treatment: drugs - Placebo

Experimental: AMG 357 - AMG 357 is a small molecule for treatment of inflammatory disease

Placebo Comparator: Placebo - Matching placebo to AMG 357 containing no active drug


Treatment: drugs: AMG 357
Oral administration available in varying dose strength.

Treatment: drugs: Placebo
Matching placebo to AMG 357 containing no active drug

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and Tolerability - Examine the number of adverse events per subject, and subject incidence of clinically significant changes in physical examinations, vital signs, laboratory safety tests and electrocardiograms, after single and multiple dose administration of AMG 357 in healthy subjects.</outcome>
      <timepoint>up to 35 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics - Measure the area under the plasma concentration curve versus time of AMG 357 after single and multiple dose administration in healthy subjects</outcome>
      <timepoint>up to 35 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effect of Food on AMG 357 - To assess the effect of food on the PK parameters of AMG 357</outcome>
      <timepoint>up to 11 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy Adult subjects between 25 and 55 years old

          -  Body mass index (BMI) between 18 and 32 kg/m2

          -  Normal or clinically acceptable physical examination, clinical laboratory values, and
             ECG

          -  Additional inclusion criteria apply</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Any history or evidence of a clinically significant disorder, condition or disease
             that would pose a risk to subject safety.

          -  Additional exclusion criteria apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>58</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton, Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study to evaluate the safety, tolerability, PK, PD, and food effect of AMG 357 in healthy
      subjects</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01695876</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>